ACRV
ACRIVON THERAPEUTICS INC

849
Loading...
Loading...
News
all
press releases
What’s the role of generative AI in drug discovery?
Investing.com -- Generative AI is emerging as a transformative long-term force in drug discovery, a field historically characterized by lengthy timelines, high costs, and low success rates.
investing.com·3mo ago
News Placeholder
More News
News Placeholder
Acrivon Therapeutics, Inc.: A Strong Buy on Robust Clinical Prospects and Financial Stability
JMP Securities analyst Silvan Tuerkcan has maintained their bullish stance on ACRV stock, giving a Buy rating yesterday. Silvan Tuerkcan's rating i...
TipRanks Financial Blog·1y ago
News Placeholder
Acrivon Therapeutics, Inc.: Strong Buy Rating on Robust Financials and Promising Clinical Data
In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV Research Report), with a pri...
TipRanks Financial Blog·1y ago
News Placeholder
Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?
Acrivon Therapeutics has entered into a securities purchase agreement to issue and sell 8.235 million shares of its common stock at a price of $8.50 per share, as well as pre-funded warrants to...
Benzinga·1y ago
News Placeholder
12 titres de soins de sant en mouvement lors de la pr -ouverture le 09/04/2024
Gagnants Le titre Acrivon Therapeutics (NASDAQ:ACRV) a mont mardi de 75,12% 10,35 dollars lors de la session pre-market. Le titre Biophytis (NASDAQ:BPTS) a augment de 40,48% 0,45 dollars. Le...
Benzinga·1y ago
News Placeholder
12 titres de soins de sant en mouvement lors de la session du 09/04/2024
Gagnants L'action Acrivon Therapeutics (NASDAQ:ACRV) a grimp mardi de 73,43% 10,25 dollars lors de la session ordinaire. L'action BioSig Technologies (NASDAQ:BSGM) a augment de 24,20% 1,54...
Benzinga·1y ago
News Placeholder
BMO Capital Markets Reiterates Outperform Rating for Acrivon Therapeutics (NASDAQ:ACRV)
Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report)s stock had its "outperform" rating restated by stock analysts at BMO Capital Markets in a research report issued on Monday, Benzinga...
Ticker Report·1y ago
News Placeholder
Buy Rating on Acrivon Therapeutics: Anticipated Clinical Validation and Strong Financial Position
Silvan Tuerkcan, an analyst from JMP Securities, maintained the Buy rating on Acrivon Therapeutics, Inc. (ACRV Research Report). The associated p...
TipRanks Financial Blog·1y ago
News Placeholder
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Increases By 22.7%
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 484,000 shares, a growth...
Zolmax·1y ago
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) Receives "Buy" Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Acrivon Therapeutics (NASDAQ:ACRV - Free Report) in a research report report published on Thursday, Benzinga reports. HC Wainwright currently has...
Ticker Report·1y ago

Latest ACRV News

View

Advertisement. Remove ads.

Advertisement. Remove ads.